Cryo-Cell International (NYSEAMERICAN:CCEL) Share Price Crosses Below Two Hundred Day Moving Average – Should You Sell?

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL)’s stock price crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.51 and traded as low as $3.45. Cryo-Cell International shares last traded at $3.56, with a volume of 1,803 shares traded.

Cryo-Cell International Trading Down 1.9%

The firm has a 50 day moving average of $3.55 and a 200-day moving average of $3.51. The company has a market cap of $28.69 million, a P/E ratio of -10.79 and a beta of 0.48.

Cryo-Cell International (NYSEAMERICAN:CCEL) last posted its quarterly earnings results on Tuesday, April 14th. The company reported $0.01 earnings per share for the quarter. The business had revenue of $7.68 million during the quarter.

Hedge Funds Weigh In On Cryo-Cell International

An institutional investor recently bought a new position in Cryo-Cell International stock. Susquehanna International Group LLP bought a new stake in shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned approximately 0.14% of Cryo-Cell International as of its most recent filing with the Securities & Exchange Commission. 10.44% of the stock is currently owned by hedge funds and other institutional investors.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.